Saniona AB (publ) (SANIOS.XC)

6.68 +0.28 (+4.37%) At close: 10:00AM BST

Saniona AB (publ)

Smedeland 26B
Glostrup 2600
Denmark
45 70 70 52 25
https://www.saniona.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 23

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jorgen Drejer Ph.D.	Founder, Chairman & Deputy CEO	350k	N/A	1955
Mr. Thomas Feldthus M.Sc., MBA	Co-Founder & CEO	2.69M	N/A	1960
Ms. Anita Milland B.Com.	Chief Financial Officer	N/A	N/A	1968
Mr. Karin Sandager Nielsen Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Mr. Palle Christophersen M.S., Ph.D.	Executive Vice President of Research	1.38M	N/A	1958
Mr. Janus Schreiber Larsen	Chief Development Officer	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company's products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome. It also develops SAN711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of absence seizures; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; and SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures. In addition, the company is developing SAN2355 to treat refractory focal onset seizures; SAN2465 to treat major depressive disorder; and other programs to treat epilepsy, Alzheimer's, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identigy and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Corporate governance

Saniona AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.